Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchiectasis | 5 | 2023 | 7 | 3.680 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 8 | 2023 | 12 | 3.350 |
Why?
|
| Lung Diseases | 5 | 2023 | 41 | 3.100 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 2023 | 3 | 1.780 |
Why?
|
| Mycobacterium avium Complex | 4 | 2023 | 4 | 1.380 |
Why?
|
| Medicare | 4 | 2023 | 192 | 1.290 |
Why?
|
| Nontuberculous Mycobacteria | 5 | 2023 | 7 | 1.170 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 143 | 1.130 |
Why?
|
| Aged | 19 | 2025 | 6084 | 1.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 107 | 1.060 |
Why?
|
| Humans | 36 | 2025 | 17314 | 0.990 |
Why?
|
| Influenza Vaccines | 2 | 2024 | 292 | 0.890 |
Why?
|
| Vaccination | 6 | 2024 | 688 | 0.890 |
Why?
|
| Influenza, Human | 2 | 2024 | 282 | 0.890 |
Why?
|
| Graft Rejection | 1 | 2024 | 4 | 0.870 |
Why?
|
| United States | 10 | 2024 | 3866 | 0.840 |
Why?
|
| Aged, 80 and over | 9 | 2024 | 1925 | 0.830 |
Why?
|
| Rifamycins | 1 | 2023 | 1 | 0.810 |
Why?
|
| Hospitalization | 3 | 2024 | 804 | 0.800 |
Why?
|
| Opportunistic Infections | 1 | 2023 | 7 | 0.800 |
Why?
|
| Communicable Diseases | 1 | 2023 | 15 | 0.790 |
Why?
|
| Male | 20 | 2025 | 9804 | 0.730 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2021 | 2 | 0.730 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 2 | 0.720 |
Why?
|
| Retrospective Studies | 12 | 2024 | 2415 | 0.720 |
Why?
|
| Female | 22 | 2025 | 12396 | 0.690 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2024 | 535 | 0.610 |
Why?
|
| Retinal Vasculitis | 3 | 2014 | 3 | 0.600 |
Why?
|
| Adult | 19 | 2025 | 7500 | 0.570 |
Why?
|
| Middle Aged | 16 | 2025 | 7836 | 0.520 |
Why?
|
| Rheumatic Diseases | 1 | 2015 | 1 | 0.480 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 24 | 0.470 |
Why?
|
| Disease Management | 1 | 2015 | 111 | 0.450 |
Why?
|
| Health Care Surveys | 1 | 2015 | 211 | 0.450 |
Why?
|
| Outpatients | 1 | 2015 | 101 | 0.450 |
Why?
|
| Patient Satisfaction | 1 | 2015 | 191 | 0.440 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 163 | 0.430 |
Why?
|
| Visual Acuity | 2 | 2014 | 18 | 0.420 |
Why?
|
| Disinfection | 1 | 2013 | 2 | 0.420 |
Why?
|
| Ethambutol | 2 | 2023 | 2 | 0.420 |
Why?
|
| Cohort Studies | 8 | 2023 | 2514 | 0.420 |
Why?
|
| Skin Diseases, Infectious | 1 | 2013 | 5 | 0.420 |
Why?
|
| Staphylococcal Infections | 1 | 2013 | 16 | 0.420 |
Why?
|
| California | 6 | 2025 | 2311 | 0.410 |
Why?
|
| Soft Tissue Infections | 1 | 2013 | 10 | 0.410 |
Why?
|
| Herpes Zoster Vaccine | 2 | 2024 | 59 | 0.390 |
Why?
|
| Case-Control Studies | 4 | 2024 | 1098 | 0.390 |
Why?
|
| Herpes Zoster | 2 | 2024 | 82 | 0.380 |
Why?
|
| Adolescent | 11 | 2025 | 3538 | 0.340 |
Why?
|
| Rifampin | 2 | 2023 | 3 | 0.330 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 1151 | 0.330 |
Why?
|
| Young Adult | 9 | 2025 | 2465 | 0.320 |
Why?
|
| Lung | 2 | 2023 | 60 | 0.310 |
Why?
|
| Risk Factors | 5 | 2025 | 3258 | 0.310 |
Why?
|
| Seasons | 2 | 2024 | 113 | 0.280 |
Why?
|
| Prospective Studies | 4 | 2023 | 1226 | 0.260 |
Why?
|
| Treatment Outcome | 5 | 2023 | 1160 | 0.260 |
Why?
|
| Regional Health Planning | 1 | 2025 | 6 | 0.230 |
Why?
|
| Tuberculosis | 1 | 2025 | 24 | 0.230 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 18 | 0.220 |
Why?
|
| Recurrence | 1 | 2024 | 165 | 0.220 |
Why?
|
| Corneal Transplantation | 1 | 2024 | 1 | 0.220 |
Why?
|
| Corneal Diseases | 1 | 2024 | 3 | 0.220 |
Why?
|
| Clarithromycin | 1 | 2023 | 1 | 0.210 |
Why?
|
| Rifabutin | 1 | 2023 | 1 | 0.210 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2024 | 12 | 0.210 |
Why?
|
| Azithromycin | 1 | 2023 | 3 | 0.210 |
Why?
|
| Societies, Medical | 1 | 2023 | 71 | 0.210 |
Why?
|
| Amikacin | 1 | 2023 | 1 | 0.200 |
Why?
|
| Macrolides | 1 | 2023 | 6 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2023 | 16 | 0.200 |
Why?
|
| Odds Ratio | 1 | 2024 | 640 | 0.190 |
Why?
|
| Electronic Health Records | 2 | 2025 | 704 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 1 | 2023 | 310 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 1 | 0.180 |
Why?
|
| Rheumatology | 1 | 2021 | 3 | 0.180 |
Why?
|
| Sex Factors | 2 | 2019 | 603 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2014 | 17 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 123 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 51 | 0.120 |
Why?
|
| Oregon | 3 | 2024 | 170 | 0.120 |
Why?
|
| Linezolid | 1 | 2015 | 1 | 0.120 |
Why?
|
| Drug Tolerance | 1 | 2015 | 2 | 0.120 |
Why?
|
| Child, Preschool | 3 | 2015 | 1380 | 0.110 |
Why?
|
| Minocycline | 1 | 2014 | 1 | 0.110 |
Why?
|
| Ofloxacin | 1 | 2014 | 1 | 0.110 |
Why?
|
| Granuloma Annulare | 1 | 2014 | 1 | 0.110 |
Why?
|
| Child | 4 | 2015 | 2403 | 0.110 |
Why?
|
| Prognosis | 2 | 2014 | 603 | 0.110 |
Why?
|
| Epiretinal Membrane | 1 | 2014 | 1 | 0.110 |
Why?
|
| Retinal Hemorrhage | 1 | 2014 | 2 | 0.110 |
Why?
|
| Retinal Neovascularization | 1 | 2014 | 2 | 0.110 |
Why?
|
| Carrier State | 1 | 2013 | 8 | 0.100 |
Why?
|
| Staphylococcus aureus | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cross Infection | 1 | 2013 | 25 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 48 | 0.100 |
Why?
|
| Herpesvirus 3, Human | 2 | 2024 | 44 | 0.100 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2012 | 1 | 0.100 |
Why?
|
| Drainage | 1 | 2012 | 2 | 0.100 |
Why?
|
| Stents | 1 | 2012 | 7 | 0.100 |
Why?
|
| Optic Neuritis | 1 | 2012 | 3 | 0.100 |
Why?
|
| Pancreatic Ducts | 1 | 2012 | 6 | 0.100 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2012 | 8 | 0.100 |
Why?
|
| Antirheumatic Agents | 1 | 2012 | 11 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 27 | 0.100 |
Why?
|
| Systemic Vasculitis | 1 | 2011 | 1 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1280 | 0.090 |
Why?
|
| Gonadal Hormones | 1 | 2011 | 1 | 0.090 |
Why?
|
| Octodon | 1 | 2011 | 1 | 0.090 |
Why?
|
| Sexual Maturation | 1 | 2011 | 8 | 0.090 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 17 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 701 | 0.080 |
Why?
|
| HIV Infections | 1 | 2017 | 712 | 0.080 |
Why?
|
| Pandemics | 2 | 2024 | 287 | 0.080 |
Why?
|
| Time Factors | 3 | 2016 | 1039 | 0.070 |
Why?
|
| Datasets as Topic | 1 | 2025 | 20 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 99 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2015 | 82 | 0.060 |
Why?
|
| Immunoglobulin G | 2 | 2016 | 29 | 0.060 |
Why?
|
| Universities | 1 | 2024 | 15 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2024 | 36 | 0.050 |
Why?
|
| China | 1 | 2024 | 132 | 0.050 |
Why?
|
| Vaccines, Combined | 1 | 2024 | 80 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2024 | 89 | 0.050 |
Why?
|
| Public Health | 1 | 2024 | 83 | 0.050 |
Why?
|
| Animals | 2 | 2016 | 280 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2023 | 72 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 5 | 0.040 |
Why?
|
| Mass Screening | 1 | 2025 | 672 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2017 | 181 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 176 | 0.030 |
Why?
|
| Viral Load | 1 | 2017 | 136 | 0.030 |
Why?
|
| Bacterial Load | 1 | 2016 | 3 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 6 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2016 | 19 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 9 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 22 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2016 | 33 | 0.030 |
Why?
|
| Cytokines | 1 | 2016 | 30 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 82 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 878 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 203 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 120 | 0.030 |
Why?
|
| Remission Induction | 1 | 2014 | 26 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 231 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2014 | 7 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 6 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 15 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2014 | 23 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2016 | 397 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2012 | 4 | 0.020 |
Why?
|
| Etanercept | 1 | 2012 | 4 | 0.020 |
Why?
|
| Adalimumab | 1 | 2012 | 4 | 0.020 |
Why?
|
| Infliximab | 1 | 2012 | 6 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 437 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 29 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 25 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 429 | 0.020 |
Why?
|
| Running | 1 | 2011 | 3 | 0.020 |
Why?
|
| Sexual Development | 1 | 2011 | 3 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 6 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2012 | 304 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 223 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 879 | 0.020 |
Why?
|
| Incidence | 1 | 2012 | 1266 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 1076 | 0.020 |
Why?
|
Concepts
(168)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->